DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
CC-220 is an investigational drug.
There have been 11 clinical trials for CC-220. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2014.
The most common disease conditions in clinical trials are Multiple Myeloma, Lupus Erythematosus, Systemic, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Celgene Corporation, Celgene, and VU University Medical Center.
There are twenty US patents protecting this investigational drug and two hundred and twelve international patents.
Recent Clinical Trials for CC-220
|Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone||Celgene||Phase 2|
|Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone||VU University Medical Center||Phase 2|
|Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects||Celgene||Phase 1|
Top disease conditions for CC-220
Top clinical trial sponsors for CC-220
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CC-220||Start Trial||Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies||Celgene Corporation (Summit, NJ)||Start Trial|
|CC-220||Start Trial||Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione||Celgene Corporation (Summit, NJ)||Start Trial|
|CC-220||Start Trial||Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast||Celgene Corporation (Summit, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|